Hangzhou Sumgen Biotech Co., Ltd.
Quick facts
Phase 3 pipeline
- SG301 · Diabetes
SG301 is a small molecule drug that targets the SGLT2 receptor.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: